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I am grateful for the opportunity to respond to the
comments by Wilde et al. The main purpose of the
study was to see if the purified chick embryo vaccine
can be administered safely using a 0.1 mL intrader-
mal (ID) dose in the Thai Red Cross regimen. This has
been proved to be effective in Thai studies and
based on this, the World Health Organization
(WHO) is likely to approve it. We are now in the
final stages of obtaining approval for the introduc-
tion of the ID route in India and wish to develop a
uniform schedule for all cell culture vaccines used
by the ID route. As this was the first study in India,
we used healthy volunteers. We have now com-
pleted a more extensive study in post-exposure
cases using good clinical practice guidelines, the
results of which are highly encouraging and about to
be published.
With regard to the estimation of rabies neutraliz-
ing antibody titers by the mouse neutralization test
(MNT), this is one of the two tests approved by WHO
for estimating neutralizing antibody titers. I am
surprised that Wilde et al. have suggested that ELISA
is better than MNT. May I remind them that ELISA
does not determine only neutralizing antibody titers
but all other viral antibodies and hence results are
bound to vary from those of MNT and RFFIT? Most
studies have shown a good correlation between
RFFIT and MNT and, as per the latest published
WHO guidelines, MNT can be used if facilities for1201-9712/$30.00 # 2004 Published by Elsevier Ltd on behalf of Int
doi:10.1016/j.ijid.2004.06.003RFFIT are not available. ELISA is not approved by
WHO.
As regards the potency of the vaccine batches
used, we simulated the actual situation in the field;
when somebody uses vaccine in the field, they will
have no facilities to determine the actual potency of
the vaccine but will follow the WHO guidelines
which clearly say that a minimum of 2.5 IU per vial
of potency is required for ID use. Keeping this in
mind, our study is valid because both the PCEC
vaccine and VeroroabTM used in our study satisfied
the above criteria of having a minimum potency of
2.5 IU/vial.
With regard to antibody titers on day 0, we did
estimate the titers on day 0 and none of our subjects
had detectable titers. This was mentioned in the
results section. Unfortunately, these data are miss-
ing from Table 1.
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